BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robson T, Worthington J, Mckeown SR, Hirst DG. Radiogenic Therapy: Novel Approaches for Enhancing Tumor Radiosensitivity. Technol Cancer Res Treat 2005;4:343-61. [DOI: 10.1177/153303460500400404] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Su C, Cao H, Tan S, Huang Y, Jia X, Jiang L, Wang K, Chen Y, Long J, Liu X. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci. 2008;106:242-250. [PMID: 18703561 DOI: 10.1093/toxsci/kfn168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kargiotis O, Geka A, Rao JS, Kyritsis AP. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol 2010;100:323-38. [PMID: 20449629 DOI: 10.1007/s11060-010-0199-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chandor A, Dijols S, Ramassamy B, Frapart Y, Mansuy D, Stuehr D, Helsby N, Boucher JL. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. Chem Res Toxicol 2008;21:836-43. [PMID: 18370414 DOI: 10.1021/tx7004234] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
4 Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007;28:4-41. [PMID: 17306358 DOI: 10.1016/j.mam.2006.12.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
5 Hsieh YJ, Hwu L, Ke CC, Huang AL, Chen FD, Wu SJ, Chen SC, Zhao YH, Liu RS. Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging. Mol Imaging Biol 2015;17:802-10. [PMID: 25962973 DOI: 10.1007/s11307-015-0843-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Kamensek U, Sersa G. Targeted gene therapy in radiotherapy. Radiology and Oncology 2008;42. [DOI: 10.2478/v10019-008-0009-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
7 Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008;270:191-201. [PMID: 18502571 DOI: 10.1016/j.canlet.2008.04.023] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
8 Li Z, Morishima S, Tang J, Otsuki Y. Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro. Med Mol Morphol 2009;42:32-9. [DOI: 10.1007/s00795-008-0424-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide. 2008;19:217-224. [PMID: 18515106 DOI: 10.1016/j.niox.2008.05.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
10 Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 2011;67:1211-24. [DOI: 10.1007/s00280-011-1654-4] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 11.9] [Reference Citation Analysis]
11 Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 2006;59:1313-23; discussion 1323-4. [PMID: 17277695 DOI: 10.1227/01.NEU.0000249218.65332.BF] [Cited by in Crossref: 52] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
12 Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol 2015;6:1-8. [PMID: 26164533 DOI: 10.1016/j.redox.2015.07.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
13 Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Adenovirus-mediated expression of Tob1 sensitizes breast cancer cells to ionizing radiation. Acta Pharmacol Sin 2007;28:1628-36. [PMID: 17883950 DOI: 10.1111/j.1745-7254.2007.00647.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
14 Kamensek U, Sersa G, Cemazar M. Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model. Mol Cancer 2013;12:136. [PMID: 24219565 DOI: 10.1186/1476-4598-12-136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
15 Garg T, Bhandari S, Rath G, Goyal AK. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target 2015;23:865-87. [PMID: 25835469 DOI: 10.3109/1061186X.2015.1029930] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
16 Mccarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, Mckeown SR, Hirst DG, Robson T. p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007;14:246-55. [DOI: 10.1038/sj.gt.3302871] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
17 Nemani KV, Ennis RC, Griswold KE, Gimi B. Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E. coli for enzyme-prodrug therapy. J Biotechnol 2015;203:32-40. [PMID: 25820125 DOI: 10.1016/j.jbiotec.2015.03.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]